Navigation Links
Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
Date:8/6/2008

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Aug. 6 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions.

CIP-ISOTRETINOIN is a novel, patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. The product received approvable letters from the U.S. Food and Drug Administration ("FDA") in May 2006 and April 2007 in which the FDA requested that Cipher provide additional clinical safety data. Cipher and its advisors are currently in discussions with the FDA's Division of Dermatology and Dental Products regarding the appropriate design of a safety study.

Under the terms of the agreement with RPI, Cipher received an initial upfront milestone payment of US$1 million. The agreement includes additional pre- and post-commercialization milestone payments of up to US$23 million, contingent upon the achievement of certain milestone targets. Once the product is successfully commercialized, Cipher will also receive a royalty in the mid-teens on net sales. In addition, RPI will reimburse Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally. Cipher is responsible for all product development activities, including management of the clinical studies required by the FDA to secure NDA approval. Cipher is also responsible for product supply and manufacturing, which would be fulfilled by its partner, Galephar Pharmaceutical Research. After product-related expenses are deducte
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ciphers revised NDA for CIP-TRAMADOL ER accepted for review by FDA
2. Cipher provides regulatory update for CIP-TRAMADOL ER
3. Cipher provides CIP-TRAMADOL ER regulatory update
4. Cipher appoints Stefan Aigner to board of directors
5. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
6. Cipher reports third quarter fiscal 2007 results
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Every Friday afternoon at A ... in Southwest Michigan, patients and staff gather in the ... the rehabilitation program and to gain encouragement and inspiration ... , One by one, those patients who have completed ... their certificates and to share a bit about their ...
(Date:5/4/2015)... UK (PRWEB) May 04, 2015 During ... witness a 7.7% CAGR. Currently, the European and APAC ... world, while the North American probiotic market lags behind ... local population. , The North American probiotic market ... over 58%), followed by Canada and Mexico. The North ...
(Date:5/4/2015)... 04, 2015 The American Council ... Thomopulos, P.E., Chairman of Stanley Consultants , to ... of directors for a three-year term. , ACEC co-established ... the American Society of Civil Engineers (ASCE). A ... system for civil infrastructure called Envision. Launched in 2012, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Global ... innovative proofreading technologies, today announced that it will ... the Music City Center, in Nashville Tennessee, May ... the world's first true all-in-one we-based packaging inspection ... in the security of their brand copy and ...
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2
... LINDA, Calif., Feb. 2 Loma Linda ... "Baby-Friendly" designation over the weekend for its efforts ... skills needed to successfully initiate and continue breastfeeding ... in the Nation to be awarded this status. ...
... Pa., Feb. 2 Employers spend more than $13 billion ... - dubbed the world,s number one health threat by the ... are more prone to injury and accidents and incur higher ... a guidepost to help employers address this issue. Health ...
... The U.S. Department of Health and Human ... of interoperability standards developed by the Healthcare ... produces "Interoperability Specifications" - documents that harmonize and ... interoperability of electronic health records and help support ...
... Pet advocates are encouraging,pet owners to focus on their ... Month this February. And it appears more Americans ... saw claims,for illnesses related to oral-health increase 179 percent ... pet owners don,t place as much emphasis on dental ...
... the role of hormone use on the risk of ... progesterone increases the risk of both ductal and lobular ... "safe" period for the use of estrogen and progesterone; ... observed in long-term past users of hormone replacement therapy ...
... Factor in Improving Formulary Placement of Newer ... New Report from HealthLeaders-InterStudy and ... Feb. 2 HealthLeaders-InterStudy and Fingertip Formulary ... pharmacy directors expect to reimburse both Bristol-Myers ...
Cached Medicine News:Health News:LLUCH is First Children's Hospital in Nation to Receive 'Baby-Friendly' Designation 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:Pet Dental Claims Skyrocket 2Health News:Study identifies potential 'safe period' for hormone replacement use 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 3
(Date:5/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... first quarter ended March 31, 2015 and provided a ... equity offering in February, which raised net proceeds ... strong financial position to advance our lead pipeline ...
(Date:5/4/2015)... 4, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... provided a regulatory update on Zalviso and reported ... 31, 2015. Zalviso Regulatory UpdateOn April ... Division of Anesthesia, Analgesia, and Addiction Products (DAAAP ...
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 3AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 4AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 6AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 7AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 8Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3
... is pleased to announce the addition of Suzie Williams , CP as ... Regional Clinical Manager.   , , ... http://www.newscom.com/cgi-bin/prnh/20100427/DA94114 ) , , , ... Suzie will be joining us as we were not only impressed by her ...
... & Reed Global Executive Search, a growing recruiting firm with offices worldwide, ... of Managing Director, Biopharmaceutical Life Sciences, effective April 15, 2010 . ... "Dave has outstanding ... recognize how important it is for our clients to work with a ...
Cached Medicine Technology:Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager 2Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences 2
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
Medicine Products: